More stories

  • in

    Angela Belcher delivers 2023 Dresselhaus Lecture on evolving organisms for new nanomaterials

    “How do we get to making nanomaterials that haven’t been evolved before?” asked Angela Belcher at the 2023 Mildred S. Dresselhaus Lecture at MIT on Nov. 20. “We can use elements that biology has already given us.”

    The combined in-person and virtual audience of over 300 was treated to a light-up, 3D model of M13 bacteriophage, a virus that only infects bacteria, complete with a pull-out strand of DNA. Belcher used the feather-boa-like model to show how her research group modifies the M13’s genes to add new DNA and peptide sequences to template inorganic materials.

    “I love controlling materials at the nanoscale using biology,” said Belcher, the James Mason Crafts Professor of Biological Engineering, materials science professor, and of the Koch Institute of Integrative Cancer Research at MIT. “We all know if you control materials at the nanoscale and you can start to tune them, then you can have all kinds of different applications.” And the opportunities are indeed vast — from building batteries, fuel cells, and solar cells to carbon sequestration and storage, environmental remediation, catalysis, and medical diagnostics and imaging.

    Belcher sprinkled her talk with models and props, lined up on a table at the front of the 10-250 lecture hall, to demonstrate a wide variety of concepts and projects made possible by the intersection of biology and nanotechnology.

    Play video

    2023 Mildred S. Dresselhaus Lecture: Angela BelcherVideo: MIT.nano

    Energy storage and environment

    “How do you go from a DNA sequence to a functioning battery?” posed Belcher. Grabbing a model of a large carbon nanotube, she explained how her group engineered a phage to pick up carbon nanotubes that would wind all the way around the virus and then fill in with different cathode or anode materials to make nanowires for battery electrodes.

    How about using the M13 bacteriophage to improve the environment? Belcher referred to a project by former student Geran Zhang PhD ’19 that proved the virus can be modified for this context, too. He used the phage to template high-surface-area, carbon-based materials that can grab small molecules and break them down, Belcher said, opening a realm of possibilities from cleaning up rivers to developing chemical warfare agents to combating smog.

    Belcher’s lab worked with the U.S. Army to produce protective clothing and masks made of these carbon-based virus nanofibers. “We went from five liters in our lab to a thousand liters, then 10,000 liters in the army labs where we’re able to make kilograms of the material,” Belcher said, stressing the importance of being able to test and prototype at scale.

    Imaging tools and therapeutics in cancer

    In the area of biomedical imaging, Belcher explained, a lot less is known in near-infrared imaging — imaging in wavelengths above 1,000 nanometers — than other imaging techniques, yet with near-infrared scientists can see much deeper inside the body. Belcher’s lab built their own systems to image at these wavelengths. The third generation of this system provides real-time, sub-millimeter optical imaging for guided surgery.

    Working with Sangeeta Bhatia, the John J. and Dorothy Wilson Professor of Engineering, Belcher used carbon nanotubes to build imaging tools that find tiny tumors during surgery that doctors otherwise would not be able to see. The tool is actually a virus engineered to carry with it a fluorescent, single-walled carbon nanotube as it seeks out the tumors.

    Nearing the end of her talk, Belcher presented a goal: to develop an accessible detection and diagnostic technology for ovarian cancer in five to 10 years.

    “We think that we can do it,” Belcher said. She described her students’ work developing a way to scan an entire fallopian tube, as opposed to just one small portion, to find pre-cancer lesions, and talked about the team of MIT faculty, doctors, and researchers working collectively toward this goal.

    “Part of the secret of life and the meaning of life is helping other people enjoy the passage of time,” said Belcher in her closing remarks. “I think that we can all do that by working to solve some of the biggest issues on the planet, including helping to diagnose and treat ovarian cancer early so people have more time to spend with their family.”

    Honoring Mildred S. Dresselhaus

    Belcher was the fifth speaker to deliver the Dresselhaus Lecture, an annual event organized by MIT.nano to honor the late MIT physics and electrical engineering Institute Professor Mildred Dresselhaus. The lecture features a speaker from anywhere in the world whose leadership and impact echo Dresselhaus’s life, accomplishments, and values.

    “Millie was and is a huge hero of mine,” said Belcher. “Giving a lecture in Millie’s name is just the greatest honor.”

    Belcher dedicated the talk to Dresselhaus, whom she described with an array of accolades — a trailblazer, a genius, an amazing mentor, teacher, and inventor. “Just knowing her was such a privilege,” she said.

    Belcher also dedicated her talk to her own grandmother and mother, both of whom passed away from cancer, as well as late MIT professors Susan Lindquist and Angelika Amon, who both died of ovarian cancer.

    “I’ve been so fortunate to work with just the most talented and dedicated graduate students, undergraduate students, postdocs, and researchers,” concluded Belcher. “It has been a pure joy to be in partnership with all of you to solve these very daunting problems.” More

  • in

    Exploring the links between diet and cancer

    Every three to five days, all of the cells lining the human intestine are replaced. That constant replenishment of cells helps the intestinal lining withstand the damage caused by food passing through the digestive tract.

    This rapid turnover of cells relies on intestinal stem cells, which give rise to all of the other types of cells found in the intestine. Recent research has shown that those stem cells are heavily influenced by diet, which can help keep them healthy or stimulate them to become cancerous.

    “Low-calorie diets such as fasting and caloric restriction can have antiaging effects and antitumor effects, and we want to understand why that is. On the other hand, diets that lead to obesity can promote diseases of aging, such as cancer,” says Omer Yilmaz, the Eisen and Chang Career Development Associate Professor of Biology at MIT.

    For the past decade, Yilmaz has been studying how different diets and environmental conditions affect intestinal stem cells, and how those factors can increase the risk of cancer and other diseases. This work could help researchers develop new ways to improve gastrointestinal health, either through dietary interventions or drugs that mimic the beneficial effects of certain diets, he says. 

    “Our findings have raised the possibility that fasting interventions, or small molecules that mimic the effects of fasting, might have a role in improving intestinal regeneration,” says Yilmaz, who is also a member of MIT’s Koch Institute for Integrative Cancer Research.

    A clinical approach

    Yilmaz’s interest in disease and medicine arose at an early age. His father practiced internal medicine, and Yilmaz spent a great deal of time at his father’s office after school, or tagging along at the hospital where his father saw patients.

    “I was very interested in medicines and how medicines were used to treat diseases,” Yilmaz recalls. “He’d ask me questions, and many times I wouldn’t know the answer, but he would encourage me to figure out the answers to his questions. That really stimulated my interest in biology and in wanting to become a doctor.”

    Knowing that he wanted to go into medicine, Yilmaz applied and was accepted to an eight-year, combined bachelor’s and MD program at the University of Michigan. As an undergraduate, this gave him the freedom to explore areas of interest without worrying about applying to medical school. While majoring in biochemistry and physics, he did undergraduate research in the field of protein folding.

    During his first year of medical school, Yilmaz realized that he missed doing research, so he decided to apply to the MD/PhD program at the University of Michigan. For his PhD research, he studied blood-forming stem cells and identified new markers that allowed such cells to be more easily isolated from the bone marrow.

    “This was important because there’s a lot of interest in understanding what makes a stem cell a stem cell, and how much of it is an internal program versus signals from the microenvironment,” Yilmaz says.

    After finishing his PhD and MD, he thought about going straight into research and skipping a medical residency, but ended up doing a residency in pathology at Massachusetts General Hospital. During that time, he decided to switch his research focus from blood-forming stem cells to stem cells found in the gastrointestinal tract.

    “The GI tract seemed very interesting because in contrast to the bone marrow, we knew very little about the identity of GI stem cells,” Yilmaz says. “I knew that once GI stem cells were identified, there’d be a lot of interesting questions about how they respond to diet and how they respond to other environmental stimuli.”

    Dietary questions

    To delve into those questions, Yilmaz did postdoctoral research at the Whitehead Institute, where he began investigating the connections between stem cells, metabolism, diet, and cancer.

    Because intestinal stem cells are so long-lived, they are more likely to accumulate genetic mutations that make them susceptible to becoming cancerous. At the Whitehead Institute, Yilmaz began studying how different diets might influence this vulnerability to cancer, a topic that he carried into his lab at MIT when he joined the faculty in 2014.

    One question his lab has been exploring is why low-calorie diets often have protective effects, including a boost in longevity — a phenomenon that has been seen in many studies in animals and humans.

    In a 2018 study, his lab found that a 24-hour fast dramatically improves stem cells’ ability to regenerate. This effect was seen in both young and aged mice, suggesting that even in old age, fasting or drugs that mimic the effects of fasting could have a beneficial effect.

    On the flip side, Yilmaz is also interested in why a high-fat diet appears to promote the development of cancer, especially colorectal cancer. In a 2016 study, he found that when mice consume a high-fat diet, it triggers a significant increase in the number of intestinal stem cells. Also, some non-stem-cell populations begin to resemble stem cells in their behavior. “The upshot of these changes is that both stem cells and non-stem-cells can give rise to tumors in a high-fat diet state,” Yilmaz says.

    To help with these studies, Yilmaz’s lab has developed a way to use mouse or human intestinal stem cells to generate miniature intestines or colons in cell culture. These “organoids” can then be exposed to different nutrients in a very controlled setting, allowing researchers to analyze how different diets affect the system.

    Recently, his lab adapted the system to allow them to expand their studies to include the role of immune cells, fibroblasts, and other supportive cells found in the microenvironment of stem cells. “It would be remiss of us to focus on just one cell type,” Yilmaz says. “We’re looking at how these different dietary interventions impact the entire stem cell neighborhood.”

    While Yilmaz spends most of his time running his lab at MIT, he also devotes six to eight weeks per year to his work at MGH, where he is an associate pathologist focusing on gastrointestinal pathology.

    “I enjoy my clinical work, and it always reminds me about the importance of the research we do,” he says. “Seeing colon cancer and other GI cancers under the microscope, and seeing their complexity, reminds me of the importance of our mission to figure out how we can prevent these cancers from forming.” More

  • in

    Paula Hammond wins faculty’s Killian Award for 2023-24

    Paula Hammond, a leading innovator in nanotechnology and head of MIT’s Department of Chemical Engineering, has been named the recipient of the 2023-2024 James R. Killian Jr. Faculty Achievement Award.

    Hammond, an MIT Institute Professor, was honored for her work designing novel polymers and nanomaterials, which have extensive applications in fields including medicine and energy.

    “Professor Hammond is a pioneer in nanotechnology research, with a program that spans from basic science to translational research in medicine and energy. She has introduced new approaches for the design and development of complex drug delivery systems for cancer treatment and non-invasive imaging,” according to the award citation, which was read at the May 17 faculty meeting by Laura Kiessling, the chair of the Killian Award Selection Committee and the Novartis Professor of Chemistry at MIT.

    Established in 1971 to honor MIT’s 10th president, James Killian, the Killian Award recognizes extraordinary professional achievements by an MIT faculty member.

    “I’ve been to past Killian Award lectures, and I’ve always thought these were the ultimate achievers at MIT in terms of their work and their science,” Hammond says. “I am incredibly honored and overwhelmed to be considered even close to a part of that group.”

    Hammond, who earned her bachelor’s degree from MIT in 1984, worked as an engineer before returning to the Institute four years later to earn a PhD, which she received in 1993. After two years as a postdoc at Harvard University, she returned to MIT again as a faculty member in 1995.

    “In a world where it isn’t always cool to be heavy into your science and your work, MIT was a place where I felt like I could just be completely myself, and that was an amazing thing,” she says.

    Since joining the faculty, Hammond has pioneered techniques for creating thin polymer films and other materials using layer-by-layer assembly. This approach can be used to build polymers with highly controlled architectures by alternately exposing a surface to positively and negatively charged particles.

    Hammond’s lab uses this technique to design materials for many different applications, including drug delivery, regenerative medicine, noninvasive imaging, and battery technology.

    Her accomplishments include designing nanoparticles that can zoom in on tumors and release their cargo when they associate with cancer cells. She has also developed nanoparticles and thin polymer films that can carry multiple drugs to a specific site and release the drugs in a controlled or staggered fashion. In recent years, much of that work has focused on potential treatments and diagnostics for ovarian cancer.

    “We’ve really had a focus on ovarian cancer over the past several years. My hope is that our work will move us in the direction of understanding how we can treat ovarian cancer, and, in collaboration with my colleagues, how we can detect it more effectively,” says Hammond, who is a member of MIT’s Koch Institute for Integrative Cancer Research.

    The award committee also cited Hammond’s record of service, both to MIT and the national scientific community. She currently serves on the President’s Council of Advisors on Science and Technology, and she is a former member of the U.S. Secretary of Energy Scientific Advisory Board. At MIT, Hammond chaired the Initiative on Faculty Race and Diversity, and co-chaired the Academic and Professional Relationships Working Group and the Implementation Team of the MIT response to the National Academies’ report entitled “Sexual Harassment of Women.”

    Among her many honors, Hammond is one of only 25 scientists who have been elected to the National Academies of Engineering, Sciences, and Medicine.

    Hammond has also been recognized for her dedication to teaching and mentoring. As a reflection of her excellence in those areas, Hammond was awarded the Irwin Sizer Award for Significant Improvements to MIT Education, the Henry Hill Lecturer Award in 2002, and the Junior Bose Faculty Award in 2000. She also co-chaired the recent Ad Hoc Committee on Faculty Advising and Mentoring, and has been selected as a “Committed to Caring” honoree for her work mentoring students and postdocs in her research group.

    “The Selection Committee is delighted to have this opportunity to honor Professor Paula Hammond, not only for her tremendous professional achievements and contributions, but also for her genuine warmth and humanity, her thoughtfulness and effective leadership, and her empathy and ethics. She is someone worth emulating. Indeed, simply put, she is the best of us,” the award committee wrote in its citation. More

  • in

    Study: Shutting down nuclear power could increase air pollution

    Nearly 20 percent of today’s electricity in the United States comes from nuclear power. The U.S. has the largest nuclear fleet in the world, with 92 reactors scattered around the country. Many of these power plants have run for more than half a century and are approaching the end of their expected lifetimes.

    Policymakers are debating whether to retire the aging reactors or reinforce their structures to continue producing nuclear energy, which many consider a low-carbon alternative to climate-warming coal, oil, and natural gas.

    Now, MIT researchers say there’s another factor to consider in weighing the future of nuclear power: air quality. In addition to being a low carbon-emitting source, nuclear power is relatively clean in terms of the air pollution it generates. Without nuclear power, how would the pattern of air pollution shift, and who would feel its effects?

    The MIT team took on these questions in a new study appearing today in Nature Energy. They lay out a scenario in which every nuclear power plant in the country has shut down, and consider how other sources such as coal, natural gas, and renewable energy would fill the resulting energy needs throughout an entire year.

    Their analysis reveals that indeed, air pollution would increase, as coal, gas, and oil sources ramp up to compensate for nuclear power’s absence. This in itself may not be surprising, but the team has put numbers to the prediction, estimating that the increase in air pollution would have serious health effects, resulting in an additional 5,200 pollution-related deaths over a single year.

    If, however, more renewable energy sources become available to supply the energy grid, as they are expected to by the year 2030, air pollution would be curtailed, though not entirely. The team found that even under this heartier renewable scenario, there is still a slight increase in air pollution in some parts of the country, resulting in a total of 260 pollution-related deaths over one year.

    When they looked at the populations directly affected by the increased pollution, they found that Black or African American communities — a disproportionate number of whom live near fossil-fuel plants — experienced the greatest exposure.

    “This adds one more layer to the environmental health and social impacts equation when you’re thinking about nuclear shutdowns, where the conversation often focuses on local risks due to accidents and mining or long-term climate impacts,” says lead author Lyssa Freese, a graduate student in MIT’s Department of Earth, Atmospheric and Planetary Sciences (EAPS).

    “In the debate over keeping nuclear power plants open, air quality has not been a focus of that discussion,” adds study author Noelle Selin, a professor in MIT’s Institute for Data, Systems, and Society (IDSS) and EAPS. “What we found was that air pollution from fossil fuel plants is so damaging, that anything that increases it, such as a nuclear shutdown, is going to have substantial impacts, and for some people more than others.”

    The study’s MIT-affiliated co-authors also include Principal Research Scientist Sebastian Eastham and Guillaume Chossière SM ’17, PhD ’20, along with Alan Jenn of the University of California at Davis.

    Future phase-outs

    When nuclear power plants have closed in the past, fossil fuel use increased in response. In 1985, the closure of reactors in Tennessee Valley prompted a spike in coal use, while the 2012 shutdown of a plant in California led to an increase in natural gas. In Germany, where nuclear power has almost completely been phased out, coal-fired power increased initially to fill the gap.

    Noting these trends, the MIT team wondered how the U.S. energy grid would respond if nuclear power were completely phased out.

    “We wanted to think about what future changes were expected in the energy grid,” Freese says. “We knew that coal use was declining, and there was a lot of work already looking at the impact of what that would have on air quality. But no one had looked at air quality and nuclear power, which we also noticed was on the decline.”

    In the new study, the team used an energy grid dispatch model developed by Jenn to assess how the U.S. energy system would respond to a shutdown of nuclear power. The model simulates the production of every power plant in the country and runs continuously to estimate, hour by hour, the energy demands in 64 regions across the country.

    Much like the way the actual energy market operates, the model chooses to turn a plant’s production up or down based on cost: Plants producing the cheapest energy at any given time are given priority to supply the grid over more costly energy sources.

    The team fed the model available data on each plant’s changing emissions and energy costs throughout an entire year. They then ran the model under different scenarios, including: an energy grid with no nuclear power, a baseline grid similar to today’s that includes nuclear power, and a grid with no nuclear power that also incorporates the additional renewable sources that are expected to be added by 2030.

    They combined each simulation with an atmospheric chemistry model to simulate how each plant’s various emissions travel around the country and to overlay these tracks onto maps of population density. For populations in the path of pollution, they calculated the risk of premature death based on their degree of exposure.

    System response

    Play video

    Courtesy of the researchers, edited by MIT News

    Their analysis showed a clear pattern: Without nuclear power, air pollution worsened in general, mainly affecting regions in the East Coast, where nuclear power plants are mostly concentrated. Without those plants, the team observed an uptick in production from coal and gas plants, resulting in 5,200 pollution-related deaths across the country, compared to the baseline scenario.

    They also calculated that more people are also likely to die prematurely due to climate impacts from the increase in carbon dioxide emissions, as the grid compensates for nuclear power’s absence. The climate-related effects from this additional influx of carbon dioxide could lead to 160,000 additional deaths over the next century.

    “We need to be thoughtful about how we’re retiring nuclear power plants if we are trying to think about them as part of an energy system,” Freese says. “Shutting down something that doesn’t have direct emissions itself can still lead to increases in emissions, because the grid system will respond.”

    “This might mean that we need to deploy even more renewables, in order to fill the hole left by nuclear, which is essentially a zero-emissions energy source,” Selin adds. “Otherwise we will have a reduction in air quality that we weren’t necessarily counting on.”

    This study was supported, in part, by the U.S. Environmental Protection Agency. More

  • in

    Two first-year students named Rise Global Winners for 2022

    In 2019, former Google CEO Eric Schmidt and his wife, Wendy, launched a $1 billion philanthropic commitment to identify global talent. Part of that effort is the Rise initiative, which selects 100 young scholars, ages 15-17, from around the world who show unusual promise and a drive to serve others. This year’s cohort of 100 Rise Global Winners includes two MIT first-year students, Jacqueline Prawira and Safiya Sankari.

    Rise intentionally targets younger-aged students and focuses on identifying what the program terms “hidden brilliance” in any form, anywhere in the world, whether it be in a high school or a refugee camp. Another defining aspect of the program is that Rise winners receive sustained support — not just in secondary school, but throughout their lives.

    “We believe that the answers to the world’s toughest problems lie in the imagination of the world’s brightest minds,” says Eric Braverman, CEO of Schmidt Futures, which manages Rise along with the Rhodes Trust. “Rise is an integral part of our mission to create the best, largest, and most enduring pipeline of exceptional talent globally and match it to opportunities to serve others for life.”

    The Rise program creates this enduring pipeline by providing a lifetime of benefits, including funding, programming, and mentoring opportunities. These resources can be tailored to each person as they evolve throughout their career. In addition to a four-year college scholarship, winners receive mentoring and career services; networking opportunities with other Rise recipients and partner organizations; technical equipment such as laptops or tablets; courses on topics like leadership and human-centered design; and opportunities to apply for graduate scholarships and for funding throughout their careers to support their innovative ideas, such as grants or seed money to start a social enterprise.

    Prawira and Sankari’s winning service projects focus on global sustainability and global medical access, respectively. Prawira invented a way to use upcycled fish-scale waste to absorb heavy metals in wastewater. She first started experimenting with fish-scale waste in middle school to try to find a bio-based alternative to plastic. More recently, she discovered that the calcium salts and collagen in fish scales can absorb up to 82 percent of heavy metals from water, and 91 percent if an electric current is passed through the water. Her work has global implications for treating contaminated water at wastewater plants and in developing countries.

    Prawiri published her research in 2021 and has won awards from the U.S. Environmental Protection Agency and several other organizations. She’s planning to major in Course 3 (materials science and engineering), perhaps with an environmentally related minor. “I believe that sustainability and solving environmental problems requires a multifaced approach,” she says. “Creating greener materials for use in our daily lives will have a major impact in solving current environmental issues.”

    For Sankari’s service project, she developed an algorithm to analyze data from electronic nano-sensor devices, or e-noses, which can detect certain diseases from a patient’s breath. The devices are calibrated to detect volatile organic compound biosignatures that are indicative of diseases like diabetes and cancer. “E-nose disease detection is much faster and cheaper than traditional methods of diagnosis, making medical care more accessible to many,” she explains. The Python-based algorithm she created can translate raw data from e-noses into a result that the user can read.

    Sankari is a lifetime member of the American Junior Academy of Science and has been a finalist in several prestigious science competitions. She is considering a major in Course 6-7 (computer science and molecular biology) at MIT and hopes to continue to explore the intersection between nanotechnology and medicine.

    While the 2022 Rise recipients share a desire to tackle some of the world’s most intractable problems, their ideas and interests, as reflected by their service projects, are broad, innovative, and diverse. A winner from Belarus used bioinformatics to predict the molecular effect of a potential Alzheimer’s drug. A Romanian student created a magazine that aims to promote acceptance of transgender bodies. A Vietnamese teen created a prototype of a toothbrush that uses a nano chip to detect cancerous cells in saliva. And a recipient from the United States designed modular, tiny homes for the unhoused that are affordable and sustainable, as an alternative to homeless shelters.

    This year’s winners were selected from over 13,000 applicants from 47 countries, from Azerbaijan and Burkina Faso to Lebanon and Paraguay. The selection process includes group interviews, peer and expert review of each applicant’s service project, and formal talent assessments. More

  • in

    How diet affects tumors

    In recent years, there has been some evidence that dietary interventions can help to slow the growth of tumors. A new study from MIT, which analyzed two different diets in mice, reveals how those diets affect cancer cells, and offers an explanation for why restricting calories may slow tumor growth.

    The study examined the effects of a calorically restricted diet and a ketogenic diet in mice with pancreatic tumors. While both of these diets reduce the amount of sugar available to tumors, the researchers found that only the calorically restricted diet reduced the availability of fatty acids, and this was linked to a slowdown in tumor growth.

    The findings do not suggest that cancer patients should try to follow either of these diets, the researchers say. Instead, they believe the findings warrant further study to determine how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.

    “There’s a lot of evidence that diet can affect how fast your cancer progresses, but this is not a cure,” says Matthew Vander Heiden, director of MIT’s Koch Institute for Integrative Cancer Research and the senior author of the study. “While the findings are provocative, further study is needed, and individual patients should talk to their doctor about the right dietary interventions for their cancer.”

    MIT postdoc Evan Lien is the lead author of the paper, which appears today in Nature.

    Metabolic mechanism

    Vander Heiden, who is also a medical oncologist at Dana-Farber Cancer Institute, says his patients often ask him about the potential benefits of various diets, but there is not enough scientific evidence available to offer any definitive advice. Many of the dietary questions that patients have focus on either a calorie-restricted diet, which reduces calorie consumption by 25 to 50 percent, or a ketogenic diet, which is low in carbohydrates and high in fat and protein.

    Previous studies have suggested that a calorically restricted diet might slow tumor growth in some contexts, and such a diet has been shown to extend lifespan in mice and many other animal species. A smaller number of studies exploring the effects of a ketogenic diet on cancer have produced inconclusive results.

    “A lot of the advice or cultural fads that are out there aren’t necessarily always based on very good science,” Lien says. “It seemed like there was an opportunity, especially with our understanding of cancer metabolism having evolved so much over the past 10 years or so, that we could take some of the biochemical principles that we’ve learned and apply those concepts to understanding this complex question.”

    Cancer cells consume a great deal of glucose, so some scientists had hypothesized that either the ketogenic diet or calorie restriction might slow tumor growth by reducing the amount of glucose available. However, the MIT team’s initial experiments in mice with pancreatic tumors showed that calorie restriction has a much greater effect on tumor growth than the ketogenic diet, so the researchers suspected that glucose levels were not playing a major role in the slowdown.

    To dig deeper into the mechanism, the researchers analyzed tumor growth and nutrient concentration in mice with pancreatic tumors, which were fed either a normal, ketogenic, or calorie-restricted diet. In both the ketogenic and calorie-restricted mice, glucose levels went down. In the calorie-restricted mice, lipid levels also went down, but in mice on the ketogenic diet, they went up.

    Lipid shortages impair tumor growth because cancer cells need lipids to construct their cell membranes. Normally, when lipids aren’t available in a tissue, cells can make their own. As part of this process, they need to maintain the right balance of saturated and unsaturated fatty acids, which requires an enzyme called stearoyl-CoA desaturase (SCD). This enzyme is responsible for converting saturated fatty acids into unsaturated fatty acids.

    Both calorie-restricted and ketogenic diets reduce SCD activity, but mice on the ketogenic diet had lipids available to them from their diet, so they didn’t need to use SCD. Mice on the calorie-restricted diet, however, couldn’t get fatty acids from their diet or produce their own. In these mice, tumor growth slowed significantly, compared to mice on the ketogenic diet.

    “Not only does caloric restriction starve tumors of lipids, it also impairs the process that allows them to adapt to it. That combination is really contributing to the inhibition of tumor growth,” Lien says.

    Dietary effects

    In addition to their mouse research, the researchers also looked at some human data. Working with Brian Wolpin, an oncologist at Dana-Farber Cancer Institute and an author of the paper, the team obtained data from a large cohort study that allowed them to analyze the relationship between dietary patterns and survival times in pancreatic cancer patients. From that study, the researchers found that the type of fat consumed appears to influence how patients on a low-sugar diet fare after a pancreatic cancer diagnosis, although the data are not complete enough to draw any conclusions about the effect of diet, the researchers say.

    Although this study showed that calorie restriction has beneficial effects in mice, the researchers say they do not recommend that cancer patients follow a calorie-restricted diet, which is difficult to maintain and can have harmful side effects. However, they believe that cancer cells’ dependence on the availability of unsaturated fatty acids could be exploited to develop drugs that might help slow tumor growth.

    One possible therapeutic strategy could be inhibition of the SCD enzyme, which would cut off tumor cells’ ability to produce unsaturated fatty acids.

    “The purpose of these studies isn’t necessarily to recommend a diet, but it’s to really understand the underlying biology,” Lien says. “They provide some sense of the mechanisms of how these diets work, and that can lead to rational ideas on how we might mimic those situations for cancer therapy.”

    The researchers now plan to study how diets with a variety of fat sources — including plant or animal-based fats with defined differences in saturated, monounsaturated, and polyunsaturated fatty acid content — alter tumor fatty acid metabolism and the ratio of unsaturated to saturated fatty acids.

    The research was funded by the Damon Runyon Cancer Research Foundation, the National Institutes of Health, the Lustgarten Foundation, the Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research, Stand Up to Cancer, the Pancreatic Cancer Action Network, the Noble Effort Fund, the Wexler Family Fund, Promises for Purple, the Bob Parsons Fund, the Emerald Foundation, the Howard Hughes Medical Institute, the MIT Center for Precision Cancer Medicine, and the Ludwig Center at MIT. More

  • in

    Institute Professor Paula Hammond named to White House science council

    Paula Hammond, an MIT Institute Professor and head of MIT’s Department of Chemical Engineering, has been chosen to serve on the President’s Council of Advisors on Science and Technology (PCAST), the White House announced today.

    The council advises the president on matters involving science, technology, education, and innovation policy. It also provides the White House with scientific and technical information that is needed to inform public policy relating to the U.S. economy, U.S. workers, and national security.

    “For me, this is an exciting opportunity,” Hammond says. “I have always been interested in considering how science can solve important problems in our community, in our country, and globally. It’s very meaningful for me to have a chance to have an advisory role at that level.”

    Hammond is one of 30 members named to the council, which is co-chaired by Frances Arnold, a professor at Caltech, and Maria Zuber, MIT’s vice president for research.

    “Paula is an extraordinary engineer, teacher, and colleague, and President Biden’s decision to appoint her to the council is an excellent one,” Zuber says. “I think about the work ahead of us — not just to restore science and technology to their proper place in policymaking, but also to make sure that they lead to real improvements in the lives of everyone in our country — and I can’t think of anyone better suited to the challenge than Paula.”

    Hammond, whose research as a chemical engineer touches on the fields of both medicine and energy, said she hopes to help address critical issues such as equal access to health care and efforts to mitigate climate change.

    “I’m very excited about the opportunities presented at the interface of engineering and health, and in particular, how we might be able to expand the benefits that we gain from our work to a broader set of communities, so that we’re able to address some of the disparities we see in health, which have been so obvious during the pandemic,” says Hammond, who is also a member of MIT’s Koch Institute for Integrative Cancer Research. “How we might be able to use everything from computational modeling and data science to technological innovation to equalize access to health is one area that I care a lot about.”

    Hammond’s research focuses on developing novel polymers and nanomaterials for a variety of applications in drug delivery, noninvasive imaging, solar cells, and battery technology. Using techniques for building polymers with highly controlled architectures, she has designed drug-delivering nanoparticles that can home in on tumors, as well as polymer films that dramatically improve the efficiency of methanol fuel cells.

    As an MIT faculty member and mentor to graduate students, Hammond has worked to increase opportunities for underrepresented minorities in science and engineering fields. That is a goal she also hopes to pursue in her new role.

    “There’s a lot of work to be done when we look at the low numbers of students of color who are actually going on to science and engineering fields,” she says. “When I think about my work related to increasing diversity in those areas, part of the reason I do it is because that’s where we gain excellence, and where we gain solutions and the foresight to work on the right problems. I also think that it’s important for there to be broad access to the power that science brings.”

    Hammond, who earned both her bachelor’s degree and PhD from MIT, has been a member of the faculty since 1995. She has been a full professor since 2006 and has chaired the Department of Chemical Engineering since 2015. Earlier this year, she was named an Institute Professor, MIT’s highest faculty honor. She is also one of only 25 people who have been elected to all three National Academies — Engineering, Science, and Medicine.

    She has previously served on the U.S. Secretary of Energy Scientific Advisory Board, the NIH Center for Scientific Review Advisory Council, and the Board of Directors of the American Institute of Chemical Engineers. She also chaired or co-chaired two committees that contributed landmark reports on gender and race at MIT: the Initiative for Faculty Race and Diversity, and the Academic and Organizational Relationships Working Group. More

  • in

    Study: Global cancer risk from burning organic matter comes from unregulated chemicals

    Whenever organic matter is burned, such as in a wildfire, a power plant, a car’s exhaust, or in daily cooking, the combustion releases polycyclic aromatic hydrocarbons (PAHs) — a class of pollutants that is known to cause lung cancer.

    There are more than 100 known types of PAH compounds emitted daily into the atmosphere. Regulators, however, have historically relied on measurements of a single compound, benzo(a)pyrene, to gauge a community’s risk of developing cancer from PAH exposure. Now MIT scientists have found that benzo(a)pyrene may be a poor indicator of this type of cancer risk.

    In a modeling study appearing today in the journal GeoHealth, the team reports that benzo(a)pyrene plays a small part — about 11 percent — in the global risk of developing PAH-associated cancer. Instead, 89 percent of that cancer risk comes from other PAH compounds, many of which are not directly regulated.

    Interestingly, about 17 percent of PAH-associated cancer risk comes from “degradation products” — chemicals that are formed when emitted PAHs react in the atmosphere. Many of these degradation products can in fact be more toxic than the emitted PAH from which they formed.

    The team hopes the results will encourage scientists and regulators to look beyond benzo(a)pyrene, to consider a broader class of PAHs when assessing a community’s cancer risk.

    “Most of the regulatory science and standards for PAHs are based on benzo(a)pyrene levels. But that is a big blind spot that could lead you down a very wrong path in terms of assessing whether cancer risk is improving or not, and whether it’s relatively worse in one place than another,” says study author Noelle Selin, a professor in MIT’s Institute for Data, Systems and Society, and the Department of Earth, Atmospheric and Planetary Sciences.

    Selin’s MIT co-authors include Jesse Kroll, Amy Hrdina, Ishwar Kohale, Forest White, and Bevin Engelward, and Jamie Kelly (who is now at University College London). Peter Ivatt and Mathew Evans at the University of York are also co-authors.

    Chemical pixels

    Benzo(a)pyrene has historically been the poster chemical for PAH exposure. The compound’s indicator status is largely based on early toxicology studies. But recent research suggests the chemical may not be the PAH representative that regulators have long relied upon.   

    “There has been a bit of evidence suggesting benzo(a)pyrene may not be very important, but this was from just a few field studies,” says Kelly, a former postdoc in Selin’s group and the study’s lead author.

    Kelly and his colleagues instead took a systematic approach to evaluate benzo(a)pyrene’s suitability as a PAH indicator. The team began by using GEOS-Chem, a global, three-dimensional chemical transport model that breaks the world into individual grid boxes and simulates within each box the reactions and concentrations of chemicals in the atmosphere.

    They extended this model to include chemical descriptions of how various PAH compounds, including benzo(a)pyrene, would react in the atmosphere. The team then plugged in recent data from emissions inventories and meteorological observations, and ran the model forward to simulate the concentrations of various PAH chemicals around the world over time.

    Risky reactions

    In their simulations, the researchers started with 16 relatively well-studied PAH chemicals, including benzo(a)pyrene, and traced the concentrations of these chemicals, plus the concentration of their degradation products over two generations, or chemical transformations. In total, the team evaluated 48 PAH species.

    They then compared these concentrations with actual concentrations of the same chemicals, recorded by monitoring stations around the world. This comparison was close enough to show that the model’s concentration predictions were realistic.

    Then within each model’s grid box, the researchers related the concentration of each PAH chemical to its associated cancer risk; to do this, they had to develop a new method based on previous studies in the literature to avoid double-counting risk from the different chemicals. Finally, they overlaid population density maps to predict the number of cancer cases globally, based on the concentration and toxicity of a specific PAH chemical in each location.

    Dividing the cancer cases by population produced the cancer risk associated with that chemical. In this way, the team calculated the cancer risk for each of the 48 compounds, then determined each chemical’s individual contribution to the total risk.

    This analysis revealed that benzo(a)pyrene had a surprisingly small contribution, of about 11 percent, to the overall risk of developing cancer from PAH exposure globally. Eighty-nine percent of cancer risk came from other chemicals. And 17 percent of this risk arose from degradation products.

    “We see places where you can find concentrations of benzo(a)pyrene are lower, but the risk is higher because of these degradation products,” Selin says. “These products can be orders of magnitude more toxic, so the fact that they’re at tiny concentrations doesn’t mean you can write them off.”

    When the researchers compared calculated PAH-associated cancer risks around the world, they found significant differences depending on whether that risk calculation was based solely on concentrations of benzo(a)pyrene or on a region’s broader mix of PAH compounds.

    “If you use the old method, you would find the lifetime cancer risk is 3.5 times higher in Hong Kong versus southern India, but taking into account the differences in PAH mixtures, you get a difference of 12 times,” Kelly says. “So, there’s a big difference in the relative cancer risk between the two places. And we think it’s important to expand the group of compounds that regulators are thinking about, beyond just a single chemical.”

    The team’s study “provides an excellent contribution to better understanding these ubiquitous pollutants,” says Elisabeth Galarneau, an air quality expert and PhD research scientist in Canada’s Department of the Environment. “It will be interesting to see how these results compare to work being done elsewhere … to pin down which (compounds) need to be tracked and considered for the protection of human and environmental health.”

    This research was conducted in MIT’s Superfund Research Center and is supported in part by the National Institute of Environmental Health Sciences Superfund Basic Research Program, and the National Institutes of Health. More